

## Special Issue

# Vaccines against Pneumococcal Infection

### Message from the Guest Editor

*Streptococcus pneumoniae* is a significant cause of community-acquired morbidity and mortality worldwide in both pediatric and adult populations. In addition to being an important cause of respiratory infections, including pneumonia and otitis media, it also is a leading cause of sepsis and meningitis. In addition to current glycoconjugate vaccines, novel formulations of pneumococcal vaccines are being developed that include non-CPS antigens and induction of Th17 immune responses that may enhance mucosal immunity. I would like to encourage submission to this special issue manuscripts that identify the distribution of pneumococcal capsular polysaccharide serotypes prevalent in various geographic locales and the impact of pneumococcal immunization. I also welcome articles that review the pathophysiology of pneumococcal infection, particularly those that identify novel targets and/or strategies for next-generation pneumococcal vaccines conferring broad coverage. Discussions of novel aspects of the immune responses to these vaccines are also desirable.

### Guest Editor

Prof. Dr. Alan Cross

Center for Vaccine Development and Global Health, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA

### Deadline for manuscript submissions

closed (30 April 2022)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/80489](https://mdpi.com/si/80489)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).